SGMT Stock Forecast: Sagimet Biosciences, Inc. Price Predictions for 2026-2027
The 12 Wall Street analysts covering Sagimet Biosciences, Inc. hold a median 12-month price target of $27 — +197.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 35 of 100 as at 21 Nov 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Sagimet Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (79): The shares have been drifting up relative to others.
Issuance (18): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
SGMT stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on SGMT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +197.4% from it.
Of the 20 most recent actions, 5 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 Nov 2026 | Canaccord Genuity | Maintains | Buy | $56 → $50 |
| 5 Oct 2026 | HC Wainwright & Co. | Reiterates | Buy | $29 |
| 2 Oct 2026 | Guggenheim | Maintains | Buy | $25 → $26 |
| 1 Oct 2026 | Citizens | Maintains | Market Outperform | $29 → $27 |
| 1 Oct 2026 | Oppenheimer | Maintains | Outperform | $33 → $38 |
| 24 Sept 2026 | Goldman Sachs | Reinstates | Sell | $7.00 |
| 9 Sept 2026 | Barclays | Upgrade | Overweight | $8.00 → $18 |
| 9 Sept 2026 | Cantor Fitzgerald | Initiates | Overweight | $11 |
| 25 Aug 2026 | HC Wainwright & Co. | Reiterates | Buy | $29 |
| 14 Aug 2026 | Citizens | Maintains | Market Outperform | $12 → $29 |
| 12 Aug 2026 | Canaccord Genuity | Maintains | Buy | $49 → $56 |
| 19 May 2026 | Citizens | Maintains | Market Outperform | $35 → $12 |
| 4 May 2026 | Canaccord Genuity | Maintains | Buy | — |
| 29 Apr 2026 | Guggenheim | Maintains | Buy | — |
| 11 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 3 Feb 2026 | Guggenheim | Initiates | Buy | — |
| 3 Feb 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 28 Jan 2026 | Barclays | Initiates | Equal-Weight | — |
| 14 Nov 2025 | Citizens | Maintains | Market Outperform | — |
| 22 Oct 2025 | Clear Street | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for SGMT.
This page is one stock. Monday covers all of them.
SGMT appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
SGMT vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Sagimet Biosciences, Inc. returned +24.9% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
SGMT analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 2.3×
- EV / EBITDA
- —
Cheaper than 38% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −29.5%
- Return on assets
- −18.2%
- Dividend yield
- —
Higher than 28% of US stocks
Higher than 21% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Sagimet Biosciences, Inc. has a market value of $692.0M and an enterprise value of $452.2M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$47.1M.
Diluted earnings per share, trailing twelve months: −$1.28.
Free cash flow in the twelve months to 30 June 2026: −$41.7M.
Sagimet Biosciences, Inc. employs 16 people.
Data provided by Twelve Data
SGMT and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at SGMT’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Sagimet Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about SGMT
What is the SGMT stock price forecast for 2026-2027?
The 12 Wall Street analysts covering Sagimet Biosciences, Inc. have a median 12-month price target of $27, with estimates ranging from $7 to $50. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is SGMT stock a buy right now?
Of the 12 analysts covering Sagimet Biosciences, Inc., 11 rate it a Buy, 0 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Sagimet Biosciences, Inc. 35 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank SGMT?
As at 21 Nov 2026, Sagimet Biosciences, Inc. ranks 35 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Momentum (79 of 100).
Will SGMT stock go up?
No one can know that. What the data says: the median 12-month target from 12 analysts implies +197.4% from the last close, and Ticker Nerd's factor model ranks Sagimet Biosciences, Inc. 35 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the SGMT stock forecast for 2030?
No analyst covering Sagimet Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SGMT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $50 over the next 12 months.
How has SGMT stock performed over the past year?
Sagimet Biosciences, Inc. returned +24.9% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Sagimet Biosciences, Inc. do?
Sagimet Biosciences Inc. Series A Common Stock represents an equity interest in Sagimet Biosciences, a clinical-stage biopharmaceutical company focused on developing novel therapeutics for metabolic and fibrotic diseases. The company’s current programs center on fatty acid synthase (FASN) inhibitors and other drug candidates designed to address dysfunctional metabolic pathways and tissue fibrosis.
About Sagimet Biosciences, Inc.
Sagimet Biosciences Inc. Series A Common Stock represents an equity interest in Sagimet Biosciences, a clinical-stage biopharmaceutical company focused on developing novel therapeutics for metabolic and fibrotic diseases. The company’s current programs center on fatty acid synthase (FASN) inhibitors and other drug candidates designed to address dysfunctional metabolic pathways and tissue fibrosis. Its lead assets include oral therapies under development for conditions such as metabolic dysfunction-associated steatohepatitis and related disorders, along with additional research programs in dermatology and oncology. Sagimet operates as a single business segment devoted to drug discovery, clinical development, and eventual commercialization of targeted therapies. The stock is used by investors to gain exposure to a specialty biotechnology company centered on in-house discovered, mechanism-based treatments for diseases with limited therapeutic options.
CEO Mr. David A. Happel · 16 employees · United States · https://www.sagimet.com